Nanobiotix Files October 2025 6-K Report

Ticker: NBTX · Form: 6-K · Filed: Oct 1, 2025 · CIK: 1760854

Sentiment: neutral

Topics: reporting, sec-filing, foreign-private-issuer

TL;DR

Nanobiotix filed its monthly 6-K, confirming standard reporting for October 2025.

AI Summary

Nanobiotix S.A. filed a Form 6-K on October 1, 2025, reporting for the month of October 2025. The company, a pharmaceutical preparations firm, is based in Paris, France, and is submitting its report under the Securities Exchange Act of 1934. Nanobiotix S.A. is confirming it files annual reports under Form 20-F.

Why It Matters

This filing indicates Nanobiotix S.A. is fulfilling its regular reporting obligations as a foreign private issuer with the SEC, providing transparency to investors.

Risk Assessment

Risk Level: low — This is a routine reporting form (6-K) that does not contain new material financial or operational information.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the registrant makes or is required to make public in its home country, files or is required to file with any stock exchange on which its securities are traded, or distributes or is required to distribute to its security holders.

What is Nanobiotix S.A.'s primary business sector?

Nanobiotix S.A. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.

Where is Nanobiotix S.A. headquartered?

Nanobiotix S.A. is headquartered at 60 Rue de Wattignies, 75012 Paris, France.

Does Nanobiotix S.A. file annual reports on Form 20-F?

Yes, Nanobiotix S.A. indicates with a check mark that it files annual reports under cover of Form 20-F.

What is the SEC file number for Nanobiotix S.A.?

The SEC file number for Nanobiotix S.A. is 001-39777.

Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2025-10-01 16:15:05

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Nanobiotix S.A. (Registrant) Date: October 1, 2025 /s/ Bart Van Rhijn Bart Van Rhijn Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing